Whitehawk Therapeutics Inc (WHWK) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.89
↑+42% vs avg
5yr avg: 1.33
30Y Low0.5·High1.8
ROE
↑
-21.8%
↓+71% vs avg
5yr avg: -74.2%
30Y Low-178%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
WHWK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Whitehawk Therapeutics Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $206M | $150M | $85M | $54M | $289M | $215M | $259M | $75M |
| Enterprise Value | $168M | $112M | $58M | $-7246640 | $251M | $67M | $265M | $67M |
| P/E Ratio → | -12.61 | — | — | — | — | — | — | — |
| P/S Ratio | 28.79 | 20.96 | 3.29 | 2.23 | 18.98 | 192.41 | 17.78 | 100.05 |
| P/B Ratio | 1.89 | 1.10 | 1.63 | 0.52 | 1.82 | 1.58 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
WHWK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 15.70 | 2.22 | -0.30 | 16.53 | 59.92 | 18.18 | 90.07 |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
WHWK Profitability
Margins and return-on-capital ratios measuring operating efficiency
Whitehawk Therapeutics Inc earns an operating margin of -1601.1%. Operating margins have compressed from -295.4% to -1601.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -21.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.4% | 89.4% | -108.0% | -112.4% | -123.4% | -1656.3% | -2.9% | -1377.2% |
| Operating Margin | -1601.1% | -1601.1% | -259.6% | -295.4% | -411.9% | -9930.1% | -17.5% | -1624.8% |
| Net Profit Margin | -288.3% | -288.3% | -245.1% | -270.0% | -397.7% | -9829.5% | -23.9% | -1636.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -21.8% | -21.8% | -80.8% | -49.9% | -41.1% | -177.6% | — | — |
| ROA | -18.6% | -18.6% | -62.8% | -41.5% | -35.4% | -124.6% | -19.6% | -73.6% |
| ROIC | -139.1% | -139.1% | -148.3% | -65.6% | -86.2% | — | — | — |
| ROCE | -120.7% | -120.7% | -84.7% | -53.0% | -40.7% | -169.3% | — | — |
WHWK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $38M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.02 | 0.01 | 0.01 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -0.53 | -0.59 | -0.24 | -1.09 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -420.91 | -311.40 | -256.33 | -55.73 | -3.13 | -144.99 |
Net cash position: cash ($38M) exceeds total debt ($0)
WHWK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Whitehawk Therapeutics Inc's current ratio of 10.26x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.72x to 10.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.26 | 10.26 | 3.59 | 4.72 | 9.56 | 9.90 | 0.62 | 0.64 |
| Quick Ratio | 10.26 | 10.26 | 3.28 | 4.48 | 9.46 | 9.90 | 0.62 | 0.64 |
| Cash Ratio | 10.03 | 10.03 | 2.77 | 4.12 | 9.16 | 9.76 | 0.15 | 0.62 |
| Asset Turnover | — | 0.05 | 0.37 | 0.18 | 0.08 | 0.01 | 0.77 | 0.04 |
| Inventory Turnover | — | — | 10.18 | 8.05 | 18.27 | — | — | — |
| Days Sales Outstanding | — | — | 82.92 | 82.25 | 44.67 | — | 354.21 | 138.83 |
WHWK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Whitehawk Therapeutics Inc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | 2.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $62M | $27M | $27M | $23M | $9M | $18M | $8M |
Peer Comparison
Compare WHWK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 WHWKYou | $206M | -12.6 | — | — | 89.4% | -1601.1% | -21.8% | -139.1% | — |
 ACAD | $4B | 9.2 | 25.1 | 34.3 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 AXSM | $13B | -69.3 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $8B | -19.8 | — | — | — | — | -45.8% | -65.0% | — |
 NRXP | $66M | -2.9 | — | — | 58.8% | -1324.4% | — | — | — |
 ATAI | $1B | -1.3 | — | — | 75.3% | -2439.7% | -389.9% | -57.0% | — |
 CMPS | $1B | -3.9 | — | — | — | — | -565.3% | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 IQV | $31B | 23.1 | 13.1 | 15.0 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -64.4 | 13.0 | 17.4 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in WHWK 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in WHWK be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs WHWK Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationWHWK vs ACAD — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs ACADIA Pharmaceuticals Inc..
Compare NowWHWK — Frequently Asked Questions
Quick answers to the most common questions about buying WHWK stock.
What is Whitehawk Therapeutics Inc's P/E ratio?
Whitehawk Therapeutics Inc's current P/E ratio is -12.6x. This places it at the 50th percentile of its historical range.
What is Whitehawk Therapeutics Inc's ROE?
Whitehawk Therapeutics Inc's return on equity (ROE) is -21.8%. The historical average is -74.2%.
Is WHWK stock overvalued?
Based on historical data, Whitehawk Therapeutics Inc is trading at a P/E of -12.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Whitehawk Therapeutics Inc's profit margins?
Whitehawk Therapeutics Inc has 89.4% gross margin and -1601.1% operating margin.